. 2020 Jun 29;111(7):2608–2619. doi: 10.1111/cas.14437

Table 1.

Clinicopathologic comparison among CD47 expression patterns in diffuse large B‐cell lymphoma

Characteristic	CD47^high (n = 71)		CD47^low (n = 49)		P value
Characteristic	No.	%	No.	%	P value
Sex (male/female)	34/37	48/52	36/13	73/27	0.005
Age (y)
Median	72		68
Range	29‐87		23‐85
>60	57/69	83	31/44	70	0.13
ECOG PS > 1	18/66	27	9/41	22	0.53
Extranodal sites > 1	4/69	6	8/43	19	0.06^*
Ann Arbor stage > 2	37/65	57	22/41	54	0.74
IPI risk group					0.62
Low (0‐2)	31/66	47	23/42	55
High (3‐5)	35/66	53	19/42	45
Hans criteria					0.01
GCB	27/68	40	29/46	63
Non‐GCB	41/68	60	17/46	37
Lymph2Cx					<0.0001
GCB	19/71	27	32/49	65
ABC	36/71	51	10/49	20
Unclassified	16/71	23	7/49	14
MYC translocation, positive	3/71	4	8/48	17	0.03^*
MYC protein, positive	38/71	54	17/49	35	0.04
DEL	22/71	31	5/49	10	0.005
EBER‐ISH, positive	2/71	3	2/49	4	1.00^*
Treatment					0.004^*
R‐CHOP/R‐CHOP‐like	70/71	99	42/49	86
Other chemotherapies	0/71	0	6/49	12
RT alone	1/71	1	1/49	2
Treatment response					0.91
CR/CRu	53/70	76	36/47	77
Not CR	17/70	24	11/47	23

Abbreviations: ABC, activated B‐cell; CR, complete response; CRu, uncertain complete response; DEL, double expressor lymphoma; EBER‐ISH, in situ hybridization for Epstein‐Barr virus‐encoded RNA; GCB, germinal center B‐cell; IPI, international prognostic index; PS, performance status; R‐CHOP, rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone; RT, radiotherapy.

Fisher’s exact test.